PHILADELPHIA –
To ensure the military medical community has the best products and services they need to tackle daily emergencies worldwide, the Defense Logistics Agency Troop Support medical supply chain worked with industry to create an active pharmaceutical ingredient quality assurance platform.
Developed through DLA’s Small Business Innovation Research program, the Provenance Pharmaceutical Solutions software catalogs and tracks medications for the warfighter. DLA started developing the platform in 2021 to assist the agency with meeting administrative executive orders and congressional mandates established in 2019.
“The program highlights where there may be problems sourcing a particular API and helps us plan for any potential supply chain interruptions,” said Air Force Lt. Col. Francisco Boral, DLA Troop Support Customer Pharmacy Operations Center division chief. “We need to consistently maintain that the highest level of supplies are available to our warfighter [and] this includes gaining a greater understanding of the pharmaceutical landscape.”
PPS can now completely map all 200 drugs on the FDA’s essential medicine list and is used in the field to train medical operations teams. DLA plans to extend PPS support to all pandemic and emergency stockpiles. Eventually, the program will partner with the Department of Health and Human Services to support the national strategic vaccine stockpile.
PPS is used by DLA to help determine if a medication is compliant with TAA which assists in ensuring that the highest quality products are acquired. The program will also further safeguard the quality of the Joint Deployment Formulary and Joint Trauma System pharmaceutical supplies that are critical to the first 30 days of a mission.
Essentially an early warning detection program for risks and potential supply disruptions due to man-made or natural disaster events, PPS also calculates overall risk analysis scores for each ingredient and key materials. Using information on item availability and potential threats to the pharmaceutical supply chain, the program alerts users when supplies of API are limited, or challenged including threatening weather, geopolitical situations, or glitches in the system that may impact availability.
“PPS identifies even the smallest risk within the supply chain with precision,” explained Navy Lt. Cmdr. Samuel Mendoza, DLA Troop Support Customer Pharmacy Operations Center branch chief. “Removing non-TAA compliant pharmaceuticals and strategically finding alternate sources makes sure our troops across the sea get the best quality pharmaceuticals. This program helps us identify problems and solutions. We do not want to be reliant on just one source for an API since we do not want local sourcing issues impacting the entire supply chain.”
To support DLA’s Whole of Government effort to help reduce redundancies across government agencies, DLA presented the PPS to stakeholders including the Office of the Assistant Secretary for Preparedness and Response Landscape Analysis Working Group, the Federal Forum at the American Pharmacist Association and the American Society of Health-System Pharmacists, the Food and Drug Administration, Department of Veterans Affairs, HHS, U.S. Pharmacopeia and Civica Rx.
The PPS is also included with the Acquisition and Medical Material Management Working Group, an intergovernmental agency overseeing sustainability of products procured by the government; and the Medical Category Management Strategic Objective, ensuring a high level of oversight.